# Nyxoah

Type: Company (NYXH)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/nyxoah
Canonical HTML page: https://gethealthbrief.com/entity/nyxoah

## Recent coverage (1 stories)

### Nyxoah and Alumis Report Q4 Earnings Misses Amid Clinical Scaling Pressures
2026-03-20 01:55:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Full story: https://gethealthbrief.com/story/nyxoah-alumis-q4-earnings-miss-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.